Drug price history · CMS NADAC read 11 November 2026
Generic
$0.431 per unit at the 2013 year-end survey (8 NDCs) and $0.099 at the 2026 survey (13 NDCs): −77%.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2013 (2013-12-25) | $0.431 | 8 | |
| 2014 (2014-12-31) | $0.470 | 9 | |
| 2015 (2015-12-30) | $0.365 | 11 | |
| 2016 (2016-12-28) | $0.285 | 14 | |
| 2017 (2017-12-27) | $0.228 | 14 | |
| 2018 (2018-12-26) | $0.188 | 14 | |
| 2019 (2019-12-25) | $0.170 | 12 | |
| 2020 (2020-12-30) | $0.161 | 8 | |
| 2021 (2021-12-29) | $0.112 | 11 | |
| 2022 (2022-12-28) | $0.101 | 11 | |
| 2023 (2023-12-27) | $0.103 | 9 | |
| 2024 (2024-12-25) | $0.096 | 10 | |
| 2025 (2025-12-31) | $0.110 | 13 | |
| 2026 (2026-11-11) | $0.099 | 13 |
Generic
$0.764 per unit at the 2013 year-end survey (5 NDCs) and $0.155 at the 2026 survey (8 NDCs): −80%.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2013 (2013-12-25) | $0.764 | 5 | |
| 2014 (2014-12-31) | $0.776 | 5 | |
| 2015 (2015-12-30) | $0.516 | 6 | |
| 2016 (2016-12-28) | $0.583 | 9 | |
| 2017 (2017-12-27) | $0.476 | 8 | |
| 2018 (2018-12-26) | $0.408 | 7 | |
| 2019 (2019-12-25) | $0.381 | 6 | |
| 2020 (2020-12-30) | $0.333 | 4 | |
| 2021 (2021-12-29) | $0.163 | 5 | |
| 2022 (2022-12-28) | $0.201 | 5 | |
| 2023 (2023-12-27) | $0.199 | 5 | |
| 2024 (2024-12-25) | $0.174 | 7 | |
| 2025 (2025-12-31) | $0.236 | 8 | |
| 2026 (2026-11-11) | $0.155 | 8 |
Generic
$0.550 per mL at the 2022 year-end survey (2 NDCs) and $0.193 at the 2026 survey (7 NDCs): −65%, a thin comparison.
| Year-end survey | Median per mL | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2022 (2022-12-28) | $0.550 | 2 | |
| 2023 (2023-12-27) | $0.486 | 3 | |
| 2024 (2024-12-25) | $0.407 | 4 | |
| 2025 (2025-12-31) | $0.229 | 7 | |
| 2026 (2026-11-11) | $0.193 | 7 |
Generic
$1.40 per mL at the 2024 year-end survey (22 NDCs) and $1.58 at the 2026 survey (20 NDCs): +13%.
| Year-end survey | Median per mL | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2024 (2024-12-25) | $1.40 | 22 | |
| 2025 (2025-12-31) | $1.51 | 22 | |
| 2026 (2026-11-11) | $1.58 | 20 |
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
The FDA Orange Book lists 16 generic makers as marketed in its largest dosage form for Glycopyrrolate, and the first generic approval is dated 24 June 1983. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.
Open it in the check to search another drug, or see the CMS pharmacy pricing page for what NADAC measures. For who makes the generic and which patents are listed, see the generic competition check for Glycopyrrolate on OmniRx. To check whether a drug is in shortage, see the FDA drug shortages page.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).